



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Derivation of the human embryonic stem cell line RCe014-A (RC-10)

Citation for published version:

De Sousa, P, Tye, BJ, Bruce, K, Dand, P, Russell, G, Collins, DM, Greenshields, A, Bradburn, H, Downie, JM, Bateman, M & Courtney, A 2016, 'Derivation of the human embryonic stem cell line RCe014-A (RC-10)' Stem cell research, vol. 16, no. 2, pp. 537-540. DOI: 10.1016/j.scr.2016.02.034

Digital Object Identifier (DOI):

[10.1016/j.scr.2016.02.034](https://doi.org/10.1016/j.scr.2016.02.034)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Stem cell research

Publisher Rights Statement:

Under a Creative Commons license


General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.





Lab Resource: Stem Cell Line

Derivation of the human embryonic stem cell line RCe014-A (RC-10)



P.A. De Sousa^{a,b,c,*}, B.J. Tye^a, K. Bruce^a, P. Dand^a, G. Russell^a, D.M. Collins^a, A. Greenshields^a, H. Bradburn^a, J.M. Downie^a, M. Bateman^a, A. Courtney^a

^a Roslin Cells Limited, Nine Edinburgh Bio-Quarter, 9 Little France Road, Edinburgh, EH16 4UX, UK

^b Centre for Clinical Brain Sciences, University of Edinburgh, UK

^c MRC Centre for Regenerative Medicine, University of Edinburgh, UK

ARTICLE INFO

Article history:

Received 16 February 2016

Accepted 19 February 2016

Available online 23 February 2016

ABSTRACT

The human embryonic stem cell line RCe014-A (RC-10) was derived from a fresh oocyte voluntarily donated as unsuitable and surplus to fertility requirements following ethics committee approved informed consent under licence from the UK Human Fertilisation and Embryology Authority. The cell line shows normal pluripotency marker expression and differentiation to the three germ layers in vitro. It has a mixed 46XY and 47XY + 12 male karyotype and microsatellite PCR identity, HLA and blood group typing data is available.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Resource table

Name of stem cell construct	RCe014-A
Alternative name	RC-10, RC10
Institution	Roslin Cells Ltd.
Person who created resource	B.J. Tye, K. Bruce, P. Dand, G. Russell, D.M. Collins, A. Greenshields, H. Bradburn
Contact person and email	Paul.desousa@roslincells.com ; Paul.desousa@ed.ac.uk Janet.downie@roslincells.com Aidan.courtney@roslincells.com Malcolm.bateman@roslinfoundation.com
Date archived/stock date	29 March 2010 (seed bank)
Type of resource	Biological reagent: cell line
Sub-type	hESC, research grade
Origin	Zygote (oocyte/1PN)
Key transcription factors	Oct4 (confirmed by flow cytometry)
Authentication	See Quality Control test summary, Table 1
Link to related literature (direct URL links and full references)	N/A
Information in public databases	http://hpsc.org.uk/cell-line/RCe014-A
Ethics	Informed consent obtained. Scotland A Research Ethics committee approval obtained (07/MRE00/56). Conducted under the UK Human Fertilisation and Embryology Authority licence no R0136 to centre 0202.

Resource details

* Corresponding author at: Centres for Clinical Brain Sciences & Regenerative Medicine University of Edinburgh Chancellor's Building, 49 Little France Crescent, Edinburgh, EH16 4SB, Scotland, UK.

E-mail addresses: paul.desousa@ed.ac.uk, paul.desousa@roslincells.com (P.A. De Sousa).

RCe014-A (RC-10) was received as a failed to fertilise oocyte/1PN (pro-nuclear) embryo that was surplus to requirement or unsuitable for clinical use. The embryo was grown to blastocyst stage and the cell line was derived by whole embryo outgrowth on mitotically inactivated human fibroblast (HDF) feeder cells using xeno-free medium (XF KODMEM) and expanded under xeno free and feeder free conditions.

By flow cytometry, RCe014-A (RC-10) expressed the pluripotency makers Oct-4, Tra-1-60 and SSEA-4 (93.4%, 94.1% and 98.9%, respectively), whereas low expression of the differentiation marker SSEA-1 (3.5%) was observed ([Fig. 1](#), [Table 1](#)). Differentiation to the three germ layers, endoderm, ectoderm and mesoderm, was demonstrated using embryoid body formation and expression of the germ layer markers α -fetoprotein, β -tubulin and muscle actin ([Fig. 2](#)).

A microsatellite PCR profile has been obtained for the cell line, and HLA Class I and II typing is available ([Table 2](#)). Blood group genotyping gave the blood group AO₁ ([Table 2](#)).

Verification and authentication

The cell line was analysed for genome stability by G-banding ([Fig. 3](#)) and showed a mixed 46XY and trisomy 12 (47XY + 12) male genotype in 12 and 3 cells analysed, respectively. The cell line is free from mycoplasma contamination as determined by RC-qPCR. Microsatellite PCR DNA profiling for cell identity is available ([Table 2](#)).

Materials and methods

Ethics

Derivation of hESC from surplus to requirement and failed to fertilise/develop oocytes and embryos was approved by The Scotland




Fig. 1. RCe014-A (RC-10) was subjected to flow cytometry analysis for markers of pluripotency with specific antibody (top row) or isotype control (bottom row) as indicated above the histograms. Percentage staining is indicated in Table 1.

A Research Ethics Committee and local ethics board at participating fertility clinics and conducted under licence no R0136 from the UK HFEA with informed donor consent.

Cell culture

Failed to activate oocytes and embryos were cultured in Sydney cleavage medium (Cook Medical, Hertfordshire, UK) until day 3 and Sydney blastocyst medium (Cook Medical) after day 3 of development. Embryos were cultured at 36.5–37.5 °C, 5 ± 0.5% CO₂, 5 ± 0.5% O₂ in drops under paraffin oil (Cook Medical) and transferred to fresh medium at least every 2–3 days.

By day 8 of development, embryos were placed in derivation conditions consisting of mitotically inactivated neonatal human dermal fibroblasts (HDFs) (Forticell Biosciences, NJ, USA) on tissue culture plastic in XF KODMEM medium (Knockout-DMEM, 15% KOSR-XF, 2 mM L-glutamine, 1% MEM Non-essential amino acids, 2% XF Growth Factor Cocktail, 0.1 mM β-mercaptoethanol, all ThermoFisher Scientific, Paisley, UK) supplemented with 80 ng/ml human bFGF (ThermoFisher Scientific).

HDF cells were cultured in DMEM (Lonza, Slough, UK), 10% Pharma grade FCS (GE Healthcare (PAA), Buckinghamshire, UK) and 2 mM L-glutamine (ThermoFisher Scientific). HDFs were mitotically inactivated using gamma irradiation at 50GY using a Gammacell Elite 1000 machine. For use as a feeder layer, irradiated HDFs were plated

at 50,000 cells/cm² in XF KODMEM medium supplemented with 80 ng/ml human bFGF (ThermoFisher Scientific). Cells were cultured at 36.5–37.5 °C, 5 ± 0.5% CO₂, 5 ± 0.5% O₂ and 50% medium exchanged 6 days a week.

The established cell line was expanded and banked using CellStart matrix and Stempro hESC Serum Free Medium (ThermoFisher Scientific). Passaging was performed mechanically using an EZ passage tool (ThermoFisher Scientific). hESC lines were expanded to 25–30 wells of a 6-well plate and cryopreserved in 0.5–1 ml Cryostor CS10 (Biolife Solution, Washington, USA).

Mycoplasma

Mycoplasma detection was performed using Applied Biosystems PrepSEQ™ Mycoplasma Nucleic Acid Extraction Kit and MicroSEQ™ Mycoplasma Real-Time PCR Detection Kit (ThermoFisher Scientific (Applied Biosystems)) according to manufacturer's instruction.

Endotoxin

Endotoxin levels were determined using the Kinetic-QCL assay (Lonza) and an incubating plate reader (BioTek ELx808) according to manufacturer's instructions. Briefly, an unknown sample was compared with a standard curve of known levels of control endotoxin. An assay was deemed valid if the coefficient of correlation, $r \geq 0.980$ and the CV (%) for the standard curve was $\leq 10\%$.

Table 1
Summary of quality control testing and results for RC-10 (RCe014-A).

Classification	Test	Purpose	Result
Donor screening	HIV 1 + 2 Hepatitis B Hepatitis C	Donor screening for adventitious agents	Negative
Identity	Microsatellite PCR (mPCR)	DNA profiling to give cell line its signature, gender/species	Performed
Phenotype	Flow cytometry	Assess antigen levels & cell surface markers commonly associated with hESC	Oct 3/4: 93.4% Tra 1-60: 94.1% SSEA-4: 98.9% SSEA-1: 3.5%
Genotype (details provided in Table 2)	Blood group genotyping (DNA analysis) Karyology (G-banding) HLA tissue typing	To establish blood group of the line Confirmation of normal ploidy by G-banding To establish full HLA type I and II genotype of the line	AO1 46XY (12 cells) 47 XY + 12 (3 cells) HLA typed class I and class II
Microbiology and virology	Mycoplasma Endotoxin	Mycoplasma testing by RT-qPCR Screening for endotoxin levels	Negative 1.2 EU/ml
Morphology	Photography	To capture a visual record of the line	Normal
Differentiation potential	Embryoid body formation	To show differentiation to three germ layers	Expression of muscle actin, β-tubulin and α-feto protein




Fig. 2. In vitro differentiation of RCe014-A (RC-10) to ectoderm (β -tubulin III), mesoderm (muscle actin), and endoderm (α -fetoprotein). Specific staining shown in green, cell nuclei are counterstained with DAPI (blue).

Table 2
Microsatellite PCR, blood group and HLA tissue typing results for RCe014-A (RC-10).

Microsatellite PCR results							
D3S1358 1	D3S1358 2	vWA 1	vWA 2	D16S539 1	D16S539 2	D2S1338 1	D2S1338 2
16	18	16	18	9	9	19	26
Amelogenin 1	Amelogenin 2	D8S1179 1	D8S1179 2	D21S11 1	D21S11 2	D18S51 1	D18S51 2
X	Y	15	15	27	28	13	13
D19S433 1	D19S433 2	THO1 1	THO1 2	FGA 1	FGA 2	CSF1PO 1	CSF1PO 2
14	15	7	9.3	24	25	10	10
D5S818 1	D5S818 2	D7S820 1	D7S820 2	D13S317 1	D13S317 2	TPOX 1	TPOX 2
Blood group genotyping							
11	11	8	12	10	13	10	11
RhD	RhC	Rhc	RhE	Rhe	Fy a	Fy b	Fy GATA
pos	pos	pos	neg	pos	neg	pos	neg
Jka	Jkb	K	k	M	N	S	S
pos	pos	neg	pos	pos	neg	pos	pos
Kp a	Kp b	Do a	Do b	ABO			
ND	ND	pos	pos	AO1			
ND = not determined							
HLA tissue typing							
HLA class I type	HLA-A*01, A*02; B*40, B*57; Cw*03, Cw*06						
HLA class II type	HLA-DRB1*01, DRB1*04; DRB4*01; DQB1*03, DQB1*05						
Comment	B*40 is expressed serologically as B60, Cw*03 is expressed serologically as Cw10, DQB1*03 is expressed serologically as DQ8						

Flow cytometry

Pluripotency was determined using the Human and Mouse Pluripotent Stem Cell Analysis kit (BD, Oxford, UK). Oct 3/4 and SSEA-4 were included as pluripotency markers, and SSEA-1 as a differentiation marker. FITC conjugated Tra-1-60 (BD) was used as an additional pluripotency marker. Fixed and permeabilised cells were analysed

using a FACS Aria flow cytometer (BD). Percentage expression of each marker was compared to isotype control or unstained cells.

Immunocytochemistry

hESC was fixed in methanol (ThermoFisher Scientific), blocked using 10% goat serum (Sigma-Aldrich, Dorset, UK) in PBS (Lonza) containing




Fig. 3. RCe014-A (RC-10) was analysed by Giesma staining and showed a mixed 46XY (12 cells) and 47XY + 12 (3 cells) male karyotype.

0.01% Tween-20 (Sigma) and stained with AFP (1:500; Sigma), β -tubulin III (1:1000; Sigma), muscle-specific actin (1:50; DAKO, Glostrup, Denmark), and secondary antibody anti-goat IgG-AlexaFluor 488 (1:200; ThermoFisher Scientific). Images were acquired using a Zeiss S100 Axiovert fluorescence microscope or Nikon eC1 confocal microscope.

In vitro differentiation

Confluent hESC cells lifted using a cell scraper (Corning) and embryoid bodies EBs generated in ultra low attachment plates (Corning) in EB medium (20% FBS (GE Healthcare (PAA)), 80% KO-DMEM 1 mM L-glutamine, 0.1 mM β -mercaptoethanol, 1% nonessential amino acids (all ThermoFisher Scientific)). After 9 days in suspension culture, EBs were being transferred onto glass slide tissue culture chambers (Nunc, ThermoFisher Scientific) coated with 0.1% gelatin (Sigma) at 0.1 ml/cm² and cultured for 14 days.

Genomic analysis

All outsourced assays were carried out under a Quality and Technical Agreement. DNA was extracted using the QIAamp DNA Mini kit (Qiagen, Manchester, UK) according to manufacturer's recommendations and provided in recommended quantities to the service providers.

Microsatellite PCR, or Short Tandem Repeat analysis, was used to determine cell line identity and was carried out by Public Health England. A profile was obtained for the following core alleles: vWA, D16S539, Amelogenin, TH01, CSF1PO, D5S818, D7S820, D13S317 and TPOX.

Human Leukocyte Antigen (HLA) tissue typing was carried out by the Scottish National Blood Transfusion Service.

Blood group genotyping was carried out by the Molecular Diagnostics laboratory at NHSBT.

Karyotype analysis was carried out by The Doctors Laboratory (London, UK) or the Western General Cytogenetics Laboratory (Edinburgh, UK). Live cells at 60–70% confluency were shipped overnight in warm containers, fixed and analysed by standard G-banding analysis. For research grade lines, 20 spreads were analysed.

Acknowledgements

Research culminating in the derivation of this line was funded by a grant from Scottish Enterprise Economic Development Agency (PM07321) to PDS, MB and AC.

Images of embryo body staining were kindly provided by S. Greenhough and J. Gardner, Roslin Cellab Ltd.